Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
97 hedge funds and large institutions have $394M invested in Y-mAbs Therapeutics in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 15 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding
Funds holding: 97 → 97 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.25% less ownership
Funds ownership: 60.22% → 58.97% (-1.3%)
45% less capital invested
Capital invested by funds: $716M → $394M (-$322M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.34M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$4.76M |
| 4 |
Morgan Stanley
New York
|
+$4.41M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$16.5M |
| 2 |
Goldman Sachs
New York
|
-$12.7M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$9.01M |
| 4 |
BC
Brookfield Corp
Toronto,
Ontario, Canada
|
-$5.12M |
| 5 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$4.83M |
YMAB Hedge Fund Activity: Q4 2021 in Review
97 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2021, worth a combined $394M — down 45% from $716M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new YMAB positions and 15 closed out — a net gain of 1 holder — while 38 added to existing stakes and 28 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $11.2M. The largest seller was First Light Asset Management, exiting entirely with an estimated $16.5M sold.
- 97 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $394M of Y-mAbs Therapeutics stock for Q4 2021, down 45% quarter-over-quarter.
- 16 funds opened new Y-mAbs Therapeutics positions in Q4 2021 and 15 closed out, a net change of +1 holder.
- The largest Y-mAbs Therapeutics buyer in Q4 2021 was AllianceBernstein, an estimated $11.2M added.
- The largest Y-mAbs Therapeutics seller in Q4 2021 was First Light Asset Management, an estimated $16.5M sold.
Based on aggregated 13F filings for Q4 2021.